Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Non-Current Debt (2019 - 2025)

Historic Non-Current Debt for China SXT Pharmaceuticals (SXTC) over the last 6 years, with Q3 2025 value amounting to $73102.0.

  • China SXT Pharmaceuticals' Non-Current Debt fell 3662.26% to $73102.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $73102.0, marking a year-over-year decrease of 3662.26%. This contributed to the annual value of $96264.0 for FY2025, which is 1781.37% down from last year.
  • As of Q3 2025, China SXT Pharmaceuticals' Non-Current Debt stood at $73102.0, which was down 3662.26% from $96264.0 recorded in Q1 2025.
  • Over the past 5 years, China SXT Pharmaceuticals' Non-Current Debt peaked at $117862.0 during Q1 2023, and registered a low of $6292.0 during Q1 2021.
  • Over the past 4 years, China SXT Pharmaceuticals' median Non-Current Debt value was $106575.0 (recorded in 2023), while the average stood at $90366.9.
  • In the last 5 years, China SXT Pharmaceuticals' Non-Current Debt plummeted by 8276.68% in 2021 and then surged by 822.8% in 2024.
  • Quarter analysis of 4 years shows China SXT Pharmaceuticals' Non-Current Debt stood at $6292.0 in 2021, then skyrocketed by 1593.82% to $106575.0 in 2023, then rose by 8.23% to $115344.0 in 2024, then tumbled by 36.62% to $73102.0 in 2025.
  • Its last three reported values are $73102.0 in Q3 2025, $96264.0 for Q1 2025, and $115344.0 during Q3 2024.